Literature DB >> 10888237

The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients.

B Liang1, J C McMaster, E A Kroeger, G M Hatch, D Mymin, T Dembinski, G Arthur, G Shen, R Y Man, P C Choy.   

Abstract

The objective of the research project was to investigate whether fenofibrate treatment may alter the biochemical content of the oxidized LDL and consequently its ability to impair the endothelium-dependent relaxation in hyperlipidemic patients. We hypothesized that fenofibrate treatment of hyperlipidemic patients may attenuate the ability of their oxidized LDL to impair the endothelium-dependent relaxation of the blood vessels as a consequence of fenofibrate-induced changes to the content and composition of lysoPC in the LDL molecule. Hyperlipidemic patients (Type IIb and Type IV) were recruited from the Lipid Clinic, HSC, Winnipeg, Canada, for this study. A blood sample was taken immediately after the recruitment, a second sample was taken after 6 weeks of dietary treatment, and a third sample was taken after 8 weeks of fenofibrate treatment. LDL was isolated from the plasma and oxidized by copper sulfate. Fenofibrate was shown to be highly effect in the reduction of total cholesterol, LDL cholesterol and triglycerides in these patients. Fenofibrate treatment also caused the attenuation of impairment of endothelium-dependent relaxation by the oxidized LDL from these patients. A slight reduction of lysophosphatidylcholine level was also found in the oxidized LDL of the fenofibrate treated patients, relative to LDL isolated after dietary treatment. In addition there were no changes in the fatty acid levels of the lysophosphatidylcholine isolated from LDL. Taken together, our results suggest that while the reduced lysophosphatidylcholine levels may contribute to the attenuated impairment of the endothelium-dependent relaxation of the aortic ring, other unidentified factors impacted by fenofibrate are likely to contribute to the attenuated effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888237     DOI: 10.1023/a:1007019019911

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  26 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

Review 2.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

3.  Receptor-mediated control of cholesterol metabolism.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1976-01-16       Impact factor: 47.728

4.  Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation.

Authors:  L Chen; B Liang; D E Froese; S Liu; J T Wong; K Tran; G M Hatch; D Mymin; E A Kroeger; R Y Man; P C Choy
Journal:  J Lipid Res       Date:  1997-03       Impact factor: 5.922

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells.

Authors:  J W Heinecke; L Baker; H Rosen; A Chait
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

7.  Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic.

Authors:  M K Cathcart; D W Morel; G M Chisolm
Journal:  J Leukoc Biol       Date:  1985-08       Impact factor: 4.962

8.  Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture.

Authors:  J W Heinecke; H Rosen; A Chait
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

9.  Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolemia.

Authors:  H Drexler; A M Zeiher
Journal:  Hypertension       Date:  1991-10       Impact factor: 10.190

10.  Glucose-enriched medium enhances cell-mediated low density lipoprotein peroxidation.

Authors:  C Mazière; M Auclair; F Rose-Robert; P Leflon; J C Mazière
Journal:  FEBS Lett       Date:  1995-04-24       Impact factor: 4.124

View more
  8 in total

1.  Effect of fenofibrate on LDL-induced endothelial dysfunction in rats.

Authors:  Tian-Lun Yang; Mei-Fang Chen; Bai-Ling Luo; Jing Yu; Jun-Lin Jiang; Yuan-Jian Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-14       Impact factor: 3.000

2.  Oxidized Low-Density Lipoprotein and the Incidence of Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema Determined From Fundus Photographs.

Authors:  Ronald Klein; Chelsea E Myers; Kristine E Lee; Andrew D Paterson; Karen J Cruickshanks; Michael Y Tsai; Ronald E Gangnon; Barbara E K Klein
Journal:  JAMA Ophthalmol       Date:  2015-09       Impact factor: 7.389

3.  Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy.

Authors:  Lingyun Li; Nerimiah Emmett; David Mann; Xueying Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2010-03

4.  Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia.

Authors:  Tian-Lun Yang; Mei-Fang Chen; Xin Xia; Bai-Lin Luo; Yuan-Jian Li
Journal:  Eur J Clin Pharmacol       Date:  2006-01-31       Impact factor: 2.953

5.  Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity.

Authors:  Tian-Lun Yang; Mei-Fang Chen; Bai-Lin Luo; Qi-Ying Xie; Jun-Lin Jiang; Yuan-Jian Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-05-25       Impact factor: 3.000

Review 6.  The Effect of Hyperlipidemia on the Course of Diabetic Retinopathy-Literature Review.

Authors:  Anna Bryl; Małgorzata Mrugacz; Mariusz Falkowski; Katarzyna Zorena
Journal:  J Clin Med       Date:  2022-05-13       Impact factor: 4.964

7.  Modified Lipoproteins in Diabetic Retinopathy: A Local Action in the Retina.

Authors:  Jeremy Y Yu; Timothy J Lyons
Journal:  J Clin Exp Ophthalmol       Date:  2013-12-18

Review 8.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.